DOAC-Remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin.

Sophie MelicineCapucine HabayWiame GhammadJulie CarréJean Luc DiehlDavid M SmadjaNicolas GendronDominique HelleyLaetitia Mauge

Published in: International journal of laboratory hematology (2024)

Our results suggest that DOAC-Remove could be of high interest in patients receiving UFH previously treated with an anti-Xa DOAC even if DOAC was stopped for more than 3 days.

Keyphrases

direct oral anticoagulants
atrial fibrillation
venous thromboembolism
oral anticoagulants
growth factor